Nanoligent

Nanoligent, a biotechnology firm established in Barcelona, Spain, is focused on creating a new generation of cancer therapies. The company was founded in December 2017 by Montserrat Cano, who brings her extensive background in molecular biology and protein biochemistry to the venture. Nanoligent operates within the biopharmaceutical sector, specifically targeting the oncology market with a novel approach to drug delivery. Its business model centers on the research and preclinical development of proprietary drug candidates, with the ultimate goal of partnering with larger pharmaceutical companies for clinical trials, manufacturing, and commercialization.

The company's core technology leverages protein engineering and nanobiotechnology to develop treatments that selectively target diseased cells, thereby increasing efficacy while minimizing the adverse effects associated with traditional chemotherapy. Nanoligent's primary project is a first-in-class drug designed to combat metastasis, which is the principal cause of mortality in most cancer patients. This therapeutic is a self-assembling protein nanoparticle that targets the CXCR4 receptor, a protein commonly over-expressed on the surface of metastatic cells across various cancer types. By targeting this receptor, the nanoparticle delivers its cytotoxic payload directly to the cancerous cells, leaving healthy tissues largely unaffected. Preclinical studies have demonstrated promising results, showing significant accumulation of the drug in tumors and metastatic sites with negligible presence in other organs, leading to a marked reduction in metastatic foci and very low toxicity. The company's current focus is on completing the necessary preclinical development to secure regulatory approval for first-in-human clinical trials.

Keywords: drug delivery, oncology, nanomedicine, anti-metastatic, CXCR4 receptor, protein nanoparticles, targeted therapy, preclinical, biopharmaceutical, cancer treatment